Vibha Ravi
Senior Editor
Vibha provides news and analysis for Pink Sheet and Scrip on a broad range of subjects related to companies, including deals, strategy, regulation and policy. Her multimedia content including infographics and podcasts have helped her win internal awards. She brings her education in business management and experience as a senior journalist for AFX-Asia to bear in spotting trends. As an attendee and panelist at conferences, she strives to bring unique insights to the audience. In her spare time, she enjoys travel, photography and blogging.
Latest From Vibha Ravi
Lupin CEO Highlights Structural Support For Generics Pricing, Sees gMyrbetriq Relaunch
Lupin’s CEO spoke of US drug shortages having led to recognition of the need for structural and regulatory support for viable pricing of generic drugs. She was also optimistic on the relaunch of a Myrbetriq generic after Astellas obtained a temporary restraining order against Lupin and Zydus just a few days post an at-risk launch by the latter two companies
Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?
The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits.
Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?
The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits. Scrip takes a look at the likely impact.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Proposed US BIOSECURE Act - Do Lonza, Other CDMOs Gain And How Soon?
Concerns over the impact of the proposed US BIOSECURE Act on the CRO and CDMO segments linger despite proponent Mike Gallagher’s plan to leave Congress soon. Which global manufacturers could gain, what determines a shift away from Chinese companies and how imminent is this? Scrip brings insights from industry feedback and other sources.